Randomized Phase II Study of Paclitaxel With or Without the Anti-IGF-IR mAb Cixutumumab (IMC-A12) as Second Line Treatment for Patients With Metastatic Esophageal or GE Junction Cancer
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 入组人数
- 94
- 试验地点
- 455
- 主要终点
- Progression-free Survival
研究概览
简要总结
This randomized phase II trial studies how well paclitaxel with or without cixutumumab works in treating patients with esophageal cancer or gastroesophageal junction cancer that has spread to other places in the body (metastatic). Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Cixutumumab may kill cancer cells by blocking the action of a protein needed for cancer cell growth. Giving paclitaxel with or without cixutumumab may kill more tumor cells.
详细描述
PRIMARY OBJECTIVES:
I. To evaluate the progression-free survival of paclitaxel plus cixutumumab (IMC-A12) versus paclitaxel alone as second-line therapy in patients with metastatic esophagus or gastroesophageal (GE) junction cancer.
SECONDARY OBJECTIVES:
I. To evaluate the overall survival of paclitaxel plus cixutumumab (IMC-A12) versus paclitaxel alone in this patient population.
II. To evaluate the response rate of paclitaxel plus cixutumumab (IMC-A12) versus paclitaxel alone in this patient population.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Life expectancy >= 12 weeks
- •Women must not be pregnant or breast-feeding due to potential harm to fetus from cixutumumab (IMC-A12) and paclitaxel; all females of childbearing potential must have a blood test or urine study within 48 hours prior to registration to rule out pregnancy
- •Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method or birth control; abstinence) for the duration of study therapy and for 3 months after the last dose of cixutumumab (IMC-A12); should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately
- •Patients must have measurable disease
- •Patients must have metastatic disease of the esophagus or gastroesophageal junction
- •Histologic, cytologic or radiologic documentation of metastatic squamous cell carcinoma or adenocarcinoma of the esophagus or gastroesophageal junction; radiologic, endoscopic, histologic or cytologic evidence of locally recurrent or locally residual (post-resection) disease is also permitted
- •For the purposes of this study, undifferentiated adenocarcinomas and adenosquamous tumors will be considered as adenocarcinomas; in addition, tumors involving the gastroesophageal junction will be defined by the Siewert classification
- •Patients with gastroesophageal junction tumors who are eligible:
- •Adenocarcinoma of the esophageal junction (AEG) Type I: adenocarcinoma of the distal esophagus which usually arises from an area with specialized intestinal metaplasia of the esophagus, i.e., Barrett's esophagus, and may infiltrate the esophagogastric junction from above
- •AEG Type II: true carcinoma of the cardia arising from the cardiac epithelium or short segments with intestinal metaplasia at the esophagogastric junction
- •Patients with gastroesophageal junction tumors who are NOT eligible:
- •AEG Type III: subcardial gastric carcinoma which infiltrates the esophagogastric junction and distal esophagus from below
- •Patients must have received and progressed on one and only one line of prior systemic therapy for esophagus or esophagogastric cancer; this could have included one regimen for metastatic disease, or one regimen with radiotherapy for initially locally advanced disease; prior radiation therapy is permitted
- •If patients progress or recur within 6 months of neoadjuvant/adjuvant therapy, this will be considered one line of therapy; for patients progressing or recurring more than 6 months after neoadjuvant/adjuvant therapy, they will need to receive one line of therapy for recurrent disease to be eligible
- •If patients receive one regimen in which a chemotherapy agent is dropped for toxicity without progression, this treatment will be considered one line of therapy; however, substitution or addition of a new agent will be considered a second line of therapy
- •Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- •Leukocytes > 3,000/mcL
- •Absolute neutrophil count >= 1,500/mcL
- •Hemoglobin >= 9 g/dL
- •Platelets >= 100,000/mcL
- •Total bilirubin =< institutional upper limit of normal (ULN)
- •Aspartate transaminase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine transaminase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 3 X institutional ULN
- •Creatinine =< 1.5 X institutional ULN or creatinine clearance >= 60 mL/min/1.73m^2 for patients with creatinine levels above institutional normal
- •Patients must have fasting serum glucose =< 160 mg/dL (8.8 mmol/L) or =< ULN, and hemoglobin A1C =< 7% (0.07 International System of Units [SI units]) within 14 days of registration; if baseline nonfasting glucose =< 160 mg/dL (8.8 mmol/L), fasting glucose measurement is not required
- •Registration no fewer than 28 days from last chemotherapy
- •A "currently active" second malignancy other than non-melanoma skin cancers are not to be registered; patients are not considered to have a "currently active" malignancy if they have completed therapy and are considered by their physician to be at less than 30% risk of relapse
排除标准
- •Patients have received prior taxane or anti-insulin growth factor receptor (IGFR) therapy
- •Patients must not have any of the following conditions:
- •Poorly controlled diabetes mellitus; patients with a history of diabetes mellitus are allowed to participate, provided that their blood glucose is within normal range (fasting glucose =< 160 mg/dL [8.8 mmol/L] or below the ULN and hemoglobin A1C =< 7% [0.07 SI units]) and that they are on a stable dietary or therapeutic regimen for this condition
- •Recent major surgery, hormonal therapy (other than replacement) or chemotherapy, within 4 weeks prior to entering the study or those who have not recovered from adverse events
- •History of allergic reactions attributed to compounds of similar chemical or biologic composition to cixutumumab (IMC-A12)
- •Psychiatric illness that would prevent the patient from giving informed consent
- •Medical conditions such as active/uncontrolled infection (including HIV) or cardiac disease that would make this protocol unreasonably hazardous for the patient in the opinion of the treating physician; cardiac disease may include uncontrolled high blood pressure, unstable angina, or serious uncontrolled cardiac arrhythmia
研究组 & 干预措施
Arm II (cixutumumab, paclitaxel)
Patients receive cixutumumab IV over 1 hour on days 1 and 15, and paclitaxel as in Arm I.
干预措施: Cixutumumab (Biological)
Arm I (paclitaxel)
Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15.
干预措施: Laboratory Biomarker Analysis (Other)
Arm II (cixutumumab, paclitaxel)
Patients receive cixutumumab IV over 1 hour on days 1 and 15, and paclitaxel as in Arm I.
干预措施: Paclitaxel (Drug)
Arm I (paclitaxel)
Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15.
干预措施: Pharmacological Study (Other)
Arm I (paclitaxel)
Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15.
干预措施: Paclitaxel (Drug)
Arm II (cixutumumab, paclitaxel)
Patients receive cixutumumab IV over 1 hour on days 1 and 15, and paclitaxel as in Arm I.
干预措施: Laboratory Biomarker Analysis (Other)
Arm II (cixutumumab, paclitaxel)
Patients receive cixutumumab IV over 1 hour on days 1 and 15, and paclitaxel as in Arm I.
干预措施: Pharmacological Study (Other)
结局指标
主要结局
Progression-free Survival
时间窗: assessed every 3 months for 2 years after registration
Progression-free survival (PFS) is defined as the time from randomization to progression or death without evidence of progression. For cases without documentation of progression, follow-up was censored at the date of last disease assessment without progression, unless death occurred within a short period of time (4 months) following the date last known progression-free, in which case the death was counted as an event, or in the case of death within 4 months of randomization in the absence of disease evaluation before that time. PFS was estimated using the Kaplan-Meier method, with 90% confidence intervals calculated using Greenwood's formula, and compared by the log rank test.
次要结局
- Overall Survival(assessed every 3 months for 2 years after registration)
- Objective Response Rate(assessed every 8 weeks while on treatment and every 3 months after treatment for 2 years)